Swiss-Dutch Call for R&D Proposals
Cell and Gene Therapy Towards Clinical Practice
Switzerland and the Netherlands are jointly announcing a bilateral call for R&D project proposals. The call is managed in line with the EUREKA initiative (www.eurekanetwork.org) by the national EUREKA offices Innosuisse and Netherlands Enterprise Agency (RVO) and the Dutch Top Sector Life Sciences & Health (Health~Holland).
Switzerland and the Netherlands strive for a small number of complementary and high-impact R&D projects. Therefore, both countries encourage and support the forming of appropriate interdisciplinary public-private consortia including key stakeholders and specialised organisations and the proper experimental contexts in both countries.
The primary focus of this call will be on stimulating public-private partnerships in translational research and clinical development of cell and gene therapies. The emphasis is on making these therapies not only clinically effective but also sustainable and affordable. Recognizing the industry-wide challenge of reducing regulatory obstacles, the goal is to expedite the process of cell and gene therapy development, ensuring faster, sustainable, and cost-effective therapies reach the market.
For more information and details, please refer to the call text at the following link: Call for R&D project proposals: Cell and Gene Therapy Towards Clinical Practice. After registration on this platform, you will be invited for the information webinar (held on March 22, 2024 - replay). Organisers warmly invite you to join the seminar and matchmaking event in Basel on April 25, 2024 as well. The seminar & matchmaking event is part of the Dutch innovation mission to Switzerland, linked to the Swiss Biotech Day. Interested Dutch organisations are invited to join the innovation mission 'Innovative Therapies Development', April 21-25, 2024. For more information and to sign up for this mission: Innovation mission Switzerland: Innovative Therapies Development (rvo.nl).
The call for project proposals is connected to the Dutch-Swiss long-term strategies in health and care laid down in the The Federal Council’s health policy strategy 2020–2030 and the Biomedical research and technology masterplan 2022-2026 in Switzerland, and the Dutch Knowledge & Innovation Agenda (KIA) on Health and Care 2020-2023 and ambitions of expertise centre Future Affordable and Sustainable Therapy development (FAST) in the Netherlands.
